LIXT

LIXTE is a clinical-stage biopharma with no product revenue since inception (the only booked figure is a stale $200K from FY2015) and, per the 10-K's own Going Concern section, does 'not expect to generate sustainable operating revenues for several years, if ever.' The entire business is optionality on LB-100, a PP2A inhibitor being tested in a handful of small Phase 1b trials. That is the definition of unknowable, binary risk — the rubric's 'avoid' case — and it is not something the provided data lets anyone underwrite with confidence.

The numbers underline the fragility. FY2025 net loss was $6.08M (worse YoY after two years of narrowing losses), operating cash burn was $3.07M, and the company held just $5.1M of cash at year-end — roughly 18 months of runway before it must return to the equity market. It already has: shares outstanding jumped 332.8% YoY, and the 10-K states outright that LIXTE 'relies on stock-based compensation for a substantial portion of employee and consultant compensation, and is dependent on periodic access to equity capital.' The accumulated deficit stands at -$58.1M against just $9.66M of book equity. For existing holders, continued dilution is not a risk — it is the stated funding model.